Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ipratropium bromide
Drug ID BADD_D01192
Description Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]
Indications and Usage For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Marketing Status Prescription; Discontinued
ATC Code R01AX03; R03BB01
DrugBank ID DB00332
KEGG ID D02212
MeSH ID D009241
PubChem ID 657308
TTD Drug ID D0S0AS
NDC Product Code 60687-394; 0591-3798; 53104-7704; 0597-0087; 60505-0826; 50090-0961; 76204-100; 53002-8410; 0378-7970; 55154-4351; 15308-1001; 16714-526; 12714-049; 0487-9801; 50090-0668; 68071-1737; 49452-3791; 66412-0753; 24208-398; 51552-1500; 24208-399; 50090-4185; 63187-188; 65862-905; 58032-0100; 70518-2874; 43235-0013; 52221-108; 59349-0013; 16714-527; 0054-0045; 0054-0046; 47335-706; 43898-0102; 70518-1070; 60505-0827
Synonyms Ipratropium | (endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane | N-Isopropylatropine | N Isopropylatropine | Atrovent | Ipratropium Bromide Anhydrous | Ipratropium Bromide, (endo,anti)-Isomer | Sch-1178 | Sch 1178 | Sch1178 | Ipratropium Bromide Monohydrate | Ipratropium Bromide, endo-Isomer | Itrop | Sch-1000 | Sch 1000 | Sch1000 | Ipratropium Bromide | Ipratropium Bromide, (exo,syn)-Isomer
Chemical Information
Molecular Formula C20H30BrNO3
CAS Registry Number 22254-24-6
SMILES CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atrial fibrillation02.03.03.002--
Bronchospasm10.01.03.012; 22.03.01.004--
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Corneal oedema06.04.02.001--Not Available
Cough22.02.03.001--
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dry throat07.06.01.005; 22.02.05.004--Not Available
Dysgeusia07.14.03.001; 17.02.07.003--
Dysphonia17.02.08.004; 19.19.03.002; 22.02.05.005--
Epistaxis22.04.03.001; 24.07.01.005--
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Glaucoma06.03.01.002--
Halo vision06.02.06.003--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hypersensitivity10.01.03.003--
Intestinal obstruction07.13.01.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.005--
The 1th Page    1 2 3    Next   Last    Total 3 Pages